Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site

Rhea-AI Summary

Evotec SE (NASDAQ:EVO) has signed a non-binding agreement with Sandoz AG for the potential sale of its Just - Evotec Biologics EU facility in Toulouse, France. The proposed transaction is valued at approximately $300 million in cash, with additional technology-related considerations including future development revenues, milestones, and product royalties.

Under the agreement, Sandoz would acquire full ownership of the Toulouse site, while Evotec maintains potential economic benefits through various revenue streams. The transaction is expected to enhance Evotec's revenue mix, profit margins, and capital efficiency. The deal's completion is subject to employee consultation processes, final agreements, and regulatory approvals.

Positive

• Significant cash consideration of $300 million
• Additional future revenue streams through development revenues, milestones, and royalties
• Expected improvement in revenue mix, profit margins, and capital efficiency
• Retention of economic upside potential while reducing operational costs

Negative

• Loss of direct control over the Toulouse biologics facility
• Transaction completion subject to multiple conditions and approvals

News Market Reaction – EVO

-1.65%

1 alert

-1.65% News Effect

On the day this news was published, EVO declined 1.65%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) regarding the potential sale of Just - Evotec Biologics EU in Toulouse, France, for a consideration of about US$ 300 m in cash. In addition, the planned transaction terms include further technology related consideration, future development revenues, milestones and product royalties.

Under the proposed terms of the transaction, Sandoz would assume full ownership of the Just - Evotec Biologics Toulouse site, while Evotec would retain short-, mid-, and long-term economic upside through revenue, milestones and royalty optionality.

The planned deal would immediately improve Evotec's revenue mix, profit margins, and capital efficiency. Closing of the planned transaction remains subject to the completion of the relevant information and consultation processes with its employees and their representatives, final contractual agreements and to meeting regulatory requirements.

- End of the ad hoc release -

Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49(0)151 1940 5058 (m), volker.braun@evotec.com

SOURCEW: Evotec SE

View the original press release on ACCESS Newswire

FAQ

What is the value of Evotec's potential sale of Just - Evotec Biologics Toulouse to Sandoz?

The deal is valued at $300 million in cash, plus additional technology-related considerations, future development revenues, milestones, and product royalties.

What will Evotec retain after selling the Toulouse facility to Sandoz?

Evotec will retain economic benefits through revenue sharing, milestone payments, and royalty opportunities while Sandoz takes full ownership of the facility.

How will the Sandoz deal affect Evotec's financial performance?

The transaction is expected to immediately improve Evotec's revenue mix, profit margins, and capital efficiency.

What conditions need to be met for the Evotec-Sandoz deal to close?

The deal requires completion of employee consultation processes, final contractual agreements, and regulatory approvals.

What type of agreement has been signed between Evotec and Sandoz?

Evotec and Sandoz have signed a non-binding agreement regarding the potential sale of the Just - Evotec Biologics EU facility in Toulouse.